Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Question
- Background (1)
- Background (2)
- Purpose
- Determining in vivo brain-to-blood efflux transport
- Clarifying molecular mechanism of BBB transport
- Proving transport function of candidate transporter
- Selected substrates
- Why GABA ?
- GABA result: in vivo transport activity
- GABA result: transport mechanism
- Why D- and L-Aspartic acid?
- Asp result: in vivo transport activity
- Asp result: transport mechanism
- Why homovanillic acid (HVA)?
- HVA result: in vivo transport activity
- HVA result: transport mechanism
- Why indoxyl sulfate (IS), uremic toxin?
- Indoxyl sulfate result: in vivo transport activity
- Indoxyl sulfate result: transport mechanism
- Why 6-mercaptopurine and 6-thioguanine?
- 6-MP and 6-TG result: in vivo transport activity (1)
- 6-MP and 6-TG result: in vivo transport activity (2)
- 6-MP and 6-TG result: transport mechanism
- Why dehydroepiandrosteron sulfate (DHEAS)?
- DHEAS result: in vivo transport activity
- DHEAS result: transport mechanism
- Why 24S-hydroxycholesterol?
- 24S-hydroxycholesterol result
- Conclusion
- Illustrated conclusion
- Perspective
- Reference (1)
- Reference (2)
- Reference (3)
- Reference (4)
Topics Covered
- The blood-brain barrier is not just a static wall, but "a cerebral clearance organ"
- The BBB multiple efflux transporters play a part in CNS detoxification by pumping out endogenous compounds from the brain
- Neurotransmitters
- Neuromodulators
- Metabolites of neurotransmitters
- Uremic toxins
- Cholesterol metabolites
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Terasaki, T. (2008, March 1). Brain-to-blood efflux transport of endogenous compounds and its analogue drug at the blood-brain barrier [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 13, 2024, from https://doi.org/10.69645/OWEN4279.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Tetsuya Terasaki has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Brain-to-blood efflux transport of endogenous compounds and its analogue drug at the blood-brain barrier
A selection of talks on Pharmaceutical Sciences
Hide